

**Medtronic Graft Delivery Syringe  
510(K) Summary – K062986  
December 2006**

DEC - 8 2006

**I. Company:** Medtronic USA, Inc.  
1800 Pyramid Place  
Memphis, TN 38132

**Contact:** Christine Scifert  
Group Director, Regulatory Affairs  
(901) 396-3133

**II. Proposed Proprietary Trade Name:** Medtronic Graft Delivery Syringe  
**Classification Name:** Piston Syringe  
**Product Code:** FMF  
**Regulation No.:** 880.5860

**III. Product Description/Purpose of Application**

The purpose of this application is to notify the FDA of our intent to market the Medtronic Graft Delivery Syringe as a means to deliver graft material to an orthopedic surgical site.

**IV. Indications**

The Medtronic Graft Delivery Syringe is intended to provide the surgeon with a means to mix autologous blood or bone marrow with allograft, autograft, demineralized bone, or synthetic bone graft materials and to deliver these materials to all orthopaedic surgical sites.

**V. Substantial Equivalence**

Documentation was provided which demonstrated the Medtronic Graft Delivery Syringe to be substantially equivalent to previously cleared graft delivery systems such as Harvest Technologies Corp.'s Harvest Graft Delivery System, (K043261, SE 03/11/05), Depuy's Symphony Graft Delivery System, K003286 (01/18/01), the Imbibe Piston Syringe (K011087, SE 09/19/01), the Imbibe Bone Marrow Aspiration Syringe (K023074, SE 03/11/03) and the Imbibe II Piston Syringe, (K030208, SE 04/16/03).



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Medtronic Sofamor Danek  
% Mr. Lee Grant  
Supervisor, Regulatory Affairs  
1800 Pyramid Place  
Memphis, Tennessee 38132

DEC - 8 2006

Re: K062986

Trade/Device Name: Medtronic Graft Delivery Syringe  
Regulation Number: 21 CFR 880.5860  
Regulation Name: Piston syringe  
Regulatory Class: II  
Product Code: FMF  
Dated: November 10, 2006  
Received: November 13, 2006

Dear Mr. Grant:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Lee Grant

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", with a long horizontal flourish extending to the right.

Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

December - 2006

510(k) Number (if known): K062986

Device Name: Medtronic Graft Delivery Syringe

Indications for Use: The Medtronic Graft Delivery Syringe is intended to provide the surgeon with a means to mix autologous blood or bone marrow with allograft, autograft, demineralized bone, or synthetic bone graft materials and to deliver these materials to all orthopaedic surgical sites.

Prescription Use  X   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of General, Restorative,  
and Neurological Devices

510(k) Number  K062986